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Esophageal strictureAbstract Objectives: To evaluate the role of fluoroscopic guided self expanding metallic stents in
the management of dysphagia caused by malignant esophageal strictures.
Materials and methods: During the period between April 2010 and October 2012, 31 patients with
malignant esophageal strictures were subjected to fluoroscopic guided self expanding metallic stent
application. The study included 22 males and 9 females ranging in age between 22 and 75 years old
with mean age of 56.8 years. Lesions were located in the lower esophagus and gastroesophageal
junction in 22 patients and middle esophagus in 9 patients.
Results: Technical success was achieved in all 31 cases (100%). The clinical success was 96.7% with
81% mean improvement in dysphagia according to dysphagia score. Only one major complication
occured (3.2%) which was proximal stent migration.
Conclusion: Fluoroscopic guided esophageal stenting is a highly effective and safe method for pal-
liating dysphagia in patients with obstructing esophageal cancer with significant clinical improve-
ment.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
The survival rates of patients with malignant esophageal
obstruction are only improved by surgical resection at a very
early stage (1). In more advanced stages, therapy is usually pal-
liative in nature, the main aims being relief of dysphagia and
maintenance of nutrition. Esophageal intubation with a
laparotomy induced plastic endoprosthesis has been practiced
for the palliation of dysphagia from malignant esophageal
obstruction. Endoscopically inserted plastic prosthesis was
812 M. Shaker et al.introduced in the 1970s, with a much reduced complication
rate. These stents had small internal diameter (10–12 mm),
resulting in many patients having difficulty in resuming a nor-
mal diet. They had a relatively high complication rate (up to
36%), mainly due to esophageal perforation, with a high
procedure-related mortality rate. Plastic stents have been
superseded by the new metallic self-expanding stents which
are considered safer and easier to place (2). The major impact
of these stents relates to the ease of their insertion and the
potential for few complications because of the small caliber
delivery system (3).
In this study we evaluate the role of Fluoroscopic guided
self expanding metallic stents in the management of dysphagia
caused by malignant esophageal strictures.
2. Materials and methods
2.1. Patient population
In this retrospective study, over a period of 30 months, thirty-
one patients with dysphagia caused by malignant esophageal
strictures were presented to Interventional Radiology Unit,
Ain Shams University hospitals, for esophageal stent applica-
tion. The study included 22 males (71%) and 9 females (29%)
ranging in age between 22 and 75 years old (mean = 56.8 -
years). Lesions were located in the lower esophagus and gas-
troesophageal junction in 22 patients (71%) and middle
esophagus in 9 patients (29%).
2.2. Inclusion criteria
Patients with irresectable esophageal cancer whether located at
middle or lower third as well as at gastro-esophageal junction
were included in the study. The treatment decision was made
after multidisciplinary discussion between surgeons and inter-
ventional radiologists on the basis of clinical and radiological
criteria.
2.3. Exclusion criteria
Patients with postcricoid carcinoma were excluded from the
study due to the intolerable foreign body pharyngeal sensa-
tion. Patients with high bleeding profile liable for uncontrol-
lable hemorrhage during or after the procedure were also
excluded on the basis of International Normalization Ratio
(INR) and platelets count; those with INR above 1.5 as well
as those with platelet count less than 50,000 were excluded
or postponed till correction of the bleeding profile. Patients
who were not fit for general anesthesia or those with very poor
general condition were excluded as well.
2.4. Patient preparation and preprocedural assessment
Full clinical and general examination was done to assess
patient’s general condition. All patients were subjected to full
history taking with stress on severity of dysphagia, so all
patients were given a score on the dysphagia score from 0 to
4 according to dysphagia scoring system, first utilized by
Knyrim et al. (4), for describing the results of stent insertion
as follows; 0 = able to eat normal diet/no dysphagia, 1 = ableto swallow some solid foods, 2 = able to swallow only semi
solid foods, 3 = able to swallow liquids only, 4 = unable to
swallow anything/absolute dysphagia.
A complete blood count and bleeding profile were obtained
within 24 h of the procedure. General laboratory studies rou-
tinely done prior to general anesthesia were also done to all
patients. Oral contrast study was done for preprocedural
assessment.
The procedure details were explained to the patients and
their relatives and a written consent was signed; in which the
risks of the procedure were clarified.
2.5. Technique
Two X-ray machines were used in the study: Toshiba machine
Infinix INFX-8000V and Toshiba machine Max 1000, all
stents were placed under general anesthesia in supine position,
a nasogastric tube was introduced till the site of the obstruc-
tion, diluted water soluble contrast medium was then injected
through the nasogastric tube to delineate the stricture, a
hydrophilic coated 180 cm guidewire (Glidewire Terumo Med-
ical Company TMC; Tokyo, Japan) was introduced through
the stricture, after bypassing the stricture the nasogastric tube
was removed and the hydrophilic guidewire was then replaced
by a superstiff guidewire (Amplatz superstiff guidewire; Bos-
ton Scientific, Natick, MA, USA) through an exchange 5F
Cobra catheter (Boston Scientific, Natick, MA, USA), the
Cobra catheter was then removed and the stent was introduced
over the stiff guidewire, the stent was then deployed after con-
firming good position under fluoroscopic guidance, and finally
contrast medium was injected again to ensure proper function
and position of the stent (Fig. 1).
Two types of partially covered self expanding nitinol stents
were used in our study according to availability in market and
in our unit: Ultraflex stent Boston Scientific, Natick, MA,
USA which was used in 25 patients with 12–15 cm stent length
and 18–23 mm stent diameter, and ChoostentTM M.I. Tech.
Co., Ltd. Seoul; Korea which was used in 6 patients with
12–17 cm stent length and 18 mm stent diameter.
In 5 patients balloon dilatation was needed prior to stent
application due to tight strictures thus facilitating the insertion
of stents, and we used the balloons as they have better radial
force and less recoil compared to the dilators, and in 2 patients
balloon dilatation was done after application. The balloon
used was CRE Wireguided Balloon Dilator, Boston Scientific,
Natick, MA, USA.
After the procedure we permitted patients to take fluids 4 h
after the procedure to allow enough time to recover from anes-
thesia and for the rest of day, the next 6 days patients were
only allowed to take semisolids. Then follow-up esophagogra-
phy was done 1 week after the procedure, if totally patent
lumen patients could take solid foods yet instructed to chew
food extensively to decrease the risk of stent obstruction. In
gastroesophageal junction tumors which was the majority of
our cases, Ranitidine; Zantac once daily at night and Domperi-
done; Motinorm 15 min before each meal were prescribed to
reduce gastroesophageal reflux through the stent. Then we fol-
lowed up the patients on monthly basis assessing the dysphagia
score.
Then we followed up the patients on monthly basis
assessing the dysphagia score for describing the results of stent
Fig. 1 Showing steps of stent insertion: (a) a water soluble contrast medium is injected to delineate the obstruction and then a
hydrophilic guidewire is introduced across the stricture into the stomach. (b) A Cobra catheter is introduced into the stomach over the
hydrophilic guidewire which is removed to be replaced by a superstiff guidewire. (c) Stent introduced over a superstiff guidewire. (d) Stent
after deployment with final esophagogram.
Malignant esophageal strictures 813insertion as follows; 0 = able to eat normal diet/no dysphagia.
1 = able to swallow some solid foods 2 = able to swallow
only semi solid foods 3 = able to swallow liquids only
4 = unable to swallow anything/absolute dysphagia. If patient
reported any difficulty or vomiting, we did a follow-up esoph-
agography to reassess stent position and function, however
there were no recorded stent stenosis in the followed patients
and no significant esophagography findings. We could follow
up 21 patients till death.2.6. Data analysis and statistics
Technical success rate was defined as successful application of
the stent across the stricture with free flow of contrast from
esophagus to the stomach. Clinical success was defined as
improvement in dysphagia at least 1 level up on the dysphagia
score. This was evaluated subjectively by the patient and by
barium swallow. Complications were defined as major (aspira-
Fig. 2 Box plot of dysphagia score comparison pre- and
postprocedural showing significant improvement of dysphagia
score poststenting.
814 M. Shaker et al.tion, bleeding, stent migration, perforation) or minor (reflux
esophagitis, chest pain, pharyngeal discomfort).
Analysis of data was done by IBM computer using SPSS
(statistical program for social science version 12) as follows.
Description of quantitative variables as mean, SD and range;
description of qualitative variables as number and percentage;
Chi-square test was used to compare qualitative variables
between groups, and Paired t-test was used for comparison
of quantities variables, in parametric data (SD< 50%) of
mean in the same group.
P value
P value > 0.05 insignificant
P< 0.05 significant
P< 0.01 highly significant (5)
3. Results
We achieved 100% technical success rate with proper position-
ing of the stent across the obstructed segment and restoring
esophageal patency.
Concerning clinical success it was evaluated subjectively
1 week after the procedure according to the dysphagia score.
One patient was admitted to the ICU few days after the proce-
dure due to severe chest infection and died 1 week later, so
clinical result of stent insertion could not be properly evaluated
in this patient, while all other patients recorded improvement
in swallowing, so clinical success rate was considered 96.7%
with 81% mean improvement in dysphagia according to dys-
phagia score.
Twenty-four patients were presented with dysphagia score
4, 5 patients with score 3 and 2 patients with score 2 with mean
dysphagia score of 3.7 which was improved to a mean grade of
0.74 after stent placement (Table 1). Thirteen patients
improved to dysphagia score 0, 11 patients to score 1, and 6
patients to score 2 within 1 week after the procedure (Fig. 2).
Concerning complications, we faced one major complica-
tion (3.2%) which is proximal stent migration 24 h after appli-
cation due to an attack of severe cough, another stent was
overlapped through the migrated stent reopening the stricture
and clinical success was evaluated after application of the sec-
ond stent (Fig. 3).
We did not consider the patient who died in ICU from chest
infection to be a complication because the mortality cause was
not procedure related. Minor bleeding occurred in 4 patients in
our study (12.9%); it was self limited and needed no further
management. No procedure related mortality. Twenty-one
patients were followed up till death and their life span ranged
between 10 days and 56 weeks with mean of 25 weeks and
stents remained functioning till death in these patients, while
10 patients were lost during follow-up.Table 1 Pre- and postprocedural dysphagia score mean and
SD.
Mean ±SD % of change t P
Pre 3.7 0.5 81% 18 <0.001
HSPost 0.77 0.34. Discussion
Esophageal cancer is often irresectable at the time of its diag-
nosis due to either local invasion or metastatic disease. The
main goals of therapy, which is usually palliative, are relief
of dysphagia with maintenance of nutrition and occlusion of
trachea-esophageal fistulas (3).
Although palliative surgery used to be an accepted method
to restore swallowing, most patients are in generally bad health
with a short life expectancy, thus forbidding surgical pallia-
tion. Several reports have been published on various other pal-
liative treatment methods. Pros and cons of chemotherapy,
radiation, application of laser beams; however, none of these
therapies is entirely satisfactory (6).
Palliation of malignant dysphagia in patients with esopha-
geal cancer or gastric cardiac cancer is the most common indi-
cation for placement of esophageal self expanding metal stents
(SEMS). These patients are judged to be inoperable because of
extensive local or regional disease or poor general status
because of advanced age, co-morbidity, or both.
There is no current consensus on absolute contraindications
for esophageal SEMS placement, but it is of utmost impor-
tance to carefully select the patients. Patients with multiple
metastases, short life expectancy (less than 4 weeks) or peri-
toneal seeding should not be considered as candidates. Patients
with high bleeding tendency who are liable for uncontrollable
hemorrhage should be also excluded (3).
Various esophageal self-expanding metal stents (SEMSs)
have recently been developed for palliative treatment of malig-
nant obstruction of the gastrointestinal tracts. The major
impact of these metallic stents is related to the ease of its inser-
tion and the potential for less complications compared with
plastic stents (3).
Stents are available in 3 types: uncovered, fully covered,
and partially covered. The original esophageal SEMS were
uncovered, with no synthetic material covering the metal mesh.
However, a variety of covering materials (most commonly
polytetrafluoroethylene) have been developed due to complica-
tions of tumor and granulation tissue ingrowth. Fully covered
stents do not have any exposed bare metal, but they are more
Fig. 3 (a) Inserted first stent is migrated above the stricture with no passage of contrast into the stomach (b) After insertion of another
stent passing through the stricture with free passage of contrast into the stomach.
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portion of exposed bare metal at the proximal and distal ends
to allow embedding into the esophageal wall, which helps to
prevent migration (7).
In an attempt to remedy the problem of reflux in distal eso-
phageal stricture after stenting, stents with antireflux mecha-
nisms have been developed as Cook Medical’s Esophageal Z-
Stent with Dua Anti-Reflux Valve (8).
SEMS have been shown to be safer and more cost-effective
than self-expandable plastic stents (SESP) used previously.
SEMS had a much lower complication rate than SEPS (9%
vs 22%, respectively). SEPS are used mainly for management
of benign esophageal strictures (9).
Biodegradable stents have recently been developed in the
hopes of avoiding the complications of tissue ingrowth and
migration and decreasing the need for reinterventions for stent
removal. Preliminary data show that these stents may provide
a valuable alternative to plastic and metal stents and may elim-
inate the need for repeat esophageal dilations. However,
biodegradable stents may also present new challenges, and fur-
ther studies are necessary (10).
In our study a 100% technical success rate was achieved
with proper positioning of the stent and successful restoration
of patency of the esophageal lumen in all patients. We used the
nasogastric tube to access the esophagus as it is less invasive
than the endoscope, also the use of nasogastric tube can be
done in supine position not in prone position like the endo-
scope and prone position is more risky than the endoscope
during anesthesia and while the endoscope has the ability to
visualize directly the site of obstruction, we can delineate the
site of obstruction using the nasogastric tube with contrast
injection.Many authors reported a technical success rate of 100%
with fluoroscopic guidance (11–15), while Cwikiel et al. (16)
achieved 97% technical success. Saxon and his colleagues
(17) carried out this on 52 patients with 96% technical success.
Clinical success was defined as improvement in dysphagia
by at least 1 level up on the dysphagia score. This definition
was applied in most of the published series. It was 100% in
Robert and Andy (12) series with decrease in mean dysphagia
score from 3 to 1. O’Sullivan and his co-authors (11) reported
95% clinical success. Tanaka et al. (13) who used partially cov-
ered SEMS as in our study adopted another approach to assess
clinical success which was food intake score which is the oppo-
site of dysphagia score (0 = complete dysphagia, 1 = liquids
only, 2 = semisolids, 3 = some solid food, 4 = normal diet).
Food intake score, which was 1 ± 0.7 (mean ± SD) before
stent placement, improved to 3.1 ± 1.3 after stent placement.
This study reported 20% clinical failure in which dysphagia
was not relieved (8 patients) but the study explained this by
the very poor clinical condition of the patients as 6 of those
8 patients died from poor general condition for various rea-
sons within 4 weeks post-stenting. In our study, we used the
dysphagia score system.
As for the aftercare of the patients, similar studies (11–13)
described nearly similar aftercare steps as that adopted in our
study; in which we permitted patients to take fluids 4 h after
the procedure to allow enough time to recover from anesthesia
and for the rest of day. The next 6 days; patients were only
allowed to take semisolids. Then follow-up esophagography
was done 1 week after the procedure, if totally patent lumen
patients could take solid foods yet instructed to chew food
extensively to decrease the risk of stent obstruction. In gastroe-
sophageal junction tumors which was the majority of our cases
816 M. Shaker et al.Ranitidine; Zantac once daily at night and Domperidone;Moti-
norm 15 min before each meal were prescribed to reduce gas-
troesophageal reflux through the stent.
Concerning complications; in one patient the stent migrated
proximally 24 h after application due to an attack of severe
cough, another stent was overlapped through the migrated
stent reopening the stricture. Minor bleeding occurred in 4
patients in our study. No perforation occurred. No aspiration
occurred. In addition, no tumor ingrowth occurred as we only
used covered stents. Most of the patients reported mild chest
pain which was more obvious in patients with gastroe-
sophageal junction tumors but needed no specific manage-
ment. Pharyngeal discomfort postprocedure was common as
well for the first few days.
Tanaka et al. (13) described complications as follows; stent
migration (occurred in one patient), massive hemorrhage
(occurred in four patients), food impaction (in one patient)
and pneumonia (in one patient). Minor hemorrhage occurred
in two patients. Aspiration pneumonia developed in one
patient with recurrent esophageal cancer after radiotherapy.
Robert and Andy (12) reported migration as the main compli-
cation of covered stents; this is particularly common in distal
esophageal lesions involving the gastro-esophageal junction,
which was 22% in this study. They mentioned the main com-
plication of uncovered stents is tumor ingrowth and over-
growth, which occurs in 17–36% of cases. Covered stents are
resistant to ingrowth but may occlude secondary to over-
growth in as many as 9% of cases. They concluded that hem-
orrhage either procedural or late hemorrhage is uncommon,
and is usually mild and self-limiting. However, severe hemor-
rhage can occur in as many as 6% of patients and this may
be related to erosion of esophageal vessels by the stent or to
local tumor invasion. O’Sullivan and Alan (11) reported that
most patients have slight discomfort on initial insertion of
the stent; in their series. Two patients had minor bleeding;
more serious bleeding is rare; in one patient erosion of the
proximal end of a stent through the esophageal lumen and sub-
sequently into the aorta occurred with fatal hemorrhage. A
further patient required radiation therapy to diminish persis-
tent mild hemorrhage after insertion of a stent.
Tanaka et al. (13) reported the death of 4 patients of mas-
sive hemorrhage but all of them were referred for stenting after
radiation therapy. O’Sullivan and his colleagues (11) reported
that; although fatal bleeding occurred in one of their patients,
this is quite rare and occurred on a background of previous
radiation therapy. The study done by Robert and Andy (12)
did not report causes of death in his study.
In our study; 21 patients died between 10 days and
56 weeks postprocedure from various conditions mostly metas-
tasis or co-morbidity but the exact causes were not very clear
in most of patients as we were reported by the deaths by phone
calls to the relatives and were reported retrospectively.
We had a number of limitations in our study, many patients
were lost in the follow-up; causes of death could not be clari-
fied in other patients as they were not admitted to the hospital
at time of death. Financial issues hindered us form trying
antireflux and antimigration stents yet migration was only seen
in one patient in our study and was proximal not distal
migration.
In conclusion, fluoroscopic guided esophageal stenting is a
highly efficient and safe tool of palliation of severe dysphagiasecondary to obstructing esophageal cancer with significant
improvement of dysphagia score.
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